The University of Rochester is a health and research institute ideally suited to help achieve the goals of the Southwest Oncology Group (SWOG). These goals include: improve standards of care to adult cancer patients advance the understanding of cancer biology via translational research, promote treatment and supportive care to outreach sites through NCI-supported clinical trial participation, explore innovative multi-modality treatment combinations, support cancer prevention efforts, and refine methodology of clinical cancer trials. Our activity (2002 -to date) as fiinded members of the Southwest Oncology Group, indicates our continuous investment in and commitment to clinical and basic laboratory research, patient care, and education. To date we have enrolled 762 cases and served as study chair or co-chair of 14 SWOG protocols;27 multidisciplinary members actively participated in one or more committees (seven faculty members served as chair and/or co-chair of 21 committees). Eleven faculty members coordinated or co-coordinated 20 protocols and 2studies currently in development. As we recruit more clinical-scientific faculty and further develop interactive, collaborative, multimodality cancer programs, we plan to produce additional important contributions to SWOG. The University of Rochester SWOG program involves 1) The University's James P. Wilmot Cancer Center and the University's Strong Memorial Hospital, a primary tertiary care center. The Cancer Center and hospital serves a population of approximately 1.4 million people 2) Six outreach facilities located In the regronal Northeast section of the country (contiguous states of New York and Massachusetts) Through this Southwest Oncology Group apphcation, our program continues to support and attain objectives to 1) participatein multi-modal Phase II/III clinical trials, 2) accelerate the advances of cancer therapy in adult patients through increased recruitment, 3) enhance basic science clinical interactions;4) support cancer control and prevention initiatives, 5) provide wide dissemination of information through quality and timely data collection and publications, 6) continueservice to the administrative agenda of the Southwest Oncology Group.

Public Health Relevance

The aim of our cooperative group participation is to advance our understanding of malignant diseases and to improve our ability to treat people. These cooperative group studies answer important therapeutic questions via large clinical trials that aim to improve prevention, treatment, and cure of adult cancers. New approaches are being developed that allow more rapid wide spread applications of therapy for adult cancers

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011083-45
Application #
8215648
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
45
Fiscal Year
2012
Total Cost
$377,652
Indirect Cost
$133,217
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Mir, Muhammad A; Maurer, Matthew J; Ziesmer, Steven C et al. (2015) Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood 125:992-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Kelly, Jennifer L; Salles, Gilles; Goldman, Bryan et al. (2015) Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol 33:1482-90
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7

Showing the most recent 10 out of 207 publications